Zenlabs Ethica Q2 Results Board Meeting Set for November 12

Zenlabs Ethica Ltd will hold a board meeting on November 12, 2026, to consider unaudited financial results for the quarter ended September 30, 2026, after reporting June-quarter sales of ₹14.18 crore, up 23.52% year-on-year, alongside a standalone net loss of ₹0.57 crore.

When will Zenlabs Ethica consider its September 2026 results?

Zenlabs Ethica has informed BSE that its Board of Directors is scheduled to meet on November 12, 2026, to consider and approve unaudited financial results for the quarter ended September 30, 2026. The disclosure identifies the approval of the quarterly results as the principal agenda item, with other matters permissible with the chair's approval.

The intimation was announced on November 6. It does not contain the September-quarter revenue, profit or loss, margin, balance-sheet, or cash-flow figures. Therefore, the board meeting notice should not be treated as a results announcement. Investors will need to wait for the board's outcome and the accompanying financial disclosure for the actual September-quarter performance.

The scheduled date is significant because it follows the company's June 2026 quarterly result, which showed improved sales but a return to loss. The forthcoming filing should indicate whether the sales growth reported in the June quarter continued and whether operating profitability changed during the September quarter.

What did Zenlabs Ethica report in the June 2026 quarter?

Zenlabs Ethica reported net sales of ₹14.18 crore for the quarter ended June 2026, compared with ₹11.48 crore in the corresponding quarter a year earlier, a rise of 23.52%. Despite the higher sales, the company recorded a standalone net loss of ₹0.57 crore, compared with a net profit of ₹0.03 crore in the June 2025 quarter.

Operating performance also weakened. Expenses were ₹14.47 crore in the June 2026 quarter, exceeding sales of ₹14.18 crore. This resulted in an operating loss of ₹0.29 crore, against an operating profit of ₹0.55 crore in the June 2025 quarter. Operating profit margin moved to negative 2.05% from a positive 4.79% a year earlier.

Reported gross profit was negative ₹0.40 crore for the June 2026 quarter, compared with positive ₹0.25 crore in the prior-year period. Earnings per share were negative ₹0.88, versus positive ₹0.05 a year earlier. The source attributes the loss movement to a significant increase in stock-in-trade expenses.

How has Zenlabs Ethica's quarterly operating trend changed?

Zenlabs Ethica's June 2026 sales were the highest in the quarterly series provided from June 2023 to June 2026. Sales increased from ₹10.58 crore in the March 2026 quarter to ₹14.18 crore in the June 2026 quarter, representing a quarter-on-quarter increase of 32.71%.

However, the increase in sales was not accompanied by a comparable improvement in costs. Expenses rose from ₹10.31 crore in March 2026 to ₹14.47 crore in June 2026. The company moved from an operating profit of ₹0.27 crore in March 2026 to an operating loss of ₹0.29 crore in June 2026.

The margin trend had already softened before the June-quarter loss. Operating profit margin was 5.35% in December 2024, 4.79% in June 2025, 3.62% in September 2025, 4.18% in December 2025, and 2.55% in March 2026. The negative margin in June 2026 makes expense control and the composition of sales important items in the next quarterly disclosure.

Why do the September-quarter results matter for investors?

The September-quarter results matter because they will provide the next set of reported figures after Zenlabs Ethica's sales growth and profitability diverged in June 2026. The available information shows revenue growth of 23.52% year-on-year, but operating loss and net loss at the same time. The upcoming disclosure can clarify whether that outcome was limited to one quarter or persisted into the September period.

For shareholders, the key reported data points will include sales, expenses, operating profit or loss, net profit or loss, earnings per share, and management disclosures accompanying the results. Any comparison with the June quarter or the September 2025 quarter should be based on the financial statement released after the board meeting rather than on estimates in the current notice.

The company previously held its 33rd annual general meeting on September 29, 2026, where shareholders adopted FY26 financial statements and reappointed key directors and auditors. Earlier, the board approved audited results for the quarter and year ended March 31, 2026, at its meeting on May 29, 2026. These events form part of the company's regular financial reporting and governance calendar.

Conclusion

Zenlabs Ethica's November 12 board meeting is a scheduled event for approving unaudited results for the quarter ended September 30, 2026, not a disclosure of those results. Its importance follows a June quarter in which sales rose to ₹14.18 crore while higher expenses led to an operating loss of ₹0.29 crore and a net loss of ₹0.57 crore.

The next item to watch is the board meeting outcome and the September-quarter financial statement. Investors can assess the updated sales trend, expense movement, margins, net result and earnings per share once Zenlabs Ethica releases the approved figures to BSE.